Summary
ICONIC-A phase 2 study of Ipilimumab, CabOzantinib, and NIvolumab in rare genitourinary (GU) cancers (ICONIC). This study includes 12 cohorts: bladder squamous cell carcinoma, bladder small cell carcinoma, bladder adenocarcinoma, bladder plasmacytoid, bladder sarcomatoid, urethra (all histologies), penile cancer, sarcomatoid RCC, collecting duct RCC, renal medullary carcinoma, bone-only non-prostate GU tumor, and miscellaneous rare GU tumors. As of Preliminarily in this study we have seen confirmed responses in the bladder squamous cell carcinoma, bladder small cell carcinoma, bladder adenocar
